271 related articles for article (PubMed ID: 8129031)
1. Immunohistochemical detection of bcl-2 protein in normal and pathological human liver.
Charlotte F; L'Herminé A; Martin N; Geleyn Y; Nollet M; Gaulard P; Zafrani ES
Am J Pathol; 1994 Mar; 144(3):460-5. PubMed ID: 8129031
[TBL] [Abstract][Full Text] [Related]
2. Topographical immunohistochemical expression of bcl-2 protein in human liver lesions.
Skopelitou A; Hadjiyannakis M; Alexopoulou V; Krikoni O; Kamina S; Agnantis N
Anticancer Res; 1996; 16(2):975-8. PubMed ID: 8687162
[TBL] [Abstract][Full Text] [Related]
3. A subgroup of intrahepatic cholangiocarcinoma with an infiltrating replacement growth pattern and a resemblance to reactive proliferating bile ductules: 'bile ductular carcinoma'.
Kozaka K; Sasaki M; Fujii T; Harada K; Zen Y; Sato Y; Sawada S; Minato H; Matsui O; Nakanuma Y
Histopathology; 2007 Sep; 51(3):390-400. PubMed ID: 17553067
[TBL] [Abstract][Full Text] [Related]
4. [Hepatic neoductules].
Fischer HP; Meybehm M; Zhou H; Schoch J
Verh Dtsch Ges Pathol; 1995; 79():36-46. PubMed ID: 8600693
[TBL] [Abstract][Full Text] [Related]
5. The expression of matrix metalloproteinases in intrahepatic cholangiocarcinoma, hilar (Klatskin tumor), middle and distal extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma: role of matrix metalloproteinases in tumor progression and prognosis.
Kirimlioğlu H; Türkmen I; Başsüllü N; Dirican A; Karadağ N; Kirimlioğlu V
Turk J Gastroenterol; 2009 Mar; 20(1):41-7. PubMed ID: 19330734
[TBL] [Abstract][Full Text] [Related]
6. High mobility group A1 is expressed in metastatic adenocarcinoma to the liver and intrahepatic cholangiocarcinoma, but not in hepatocellular carcinoma: its potential use in the diagnosis of liver neoplasms.
Abe N; Watanabe T; Izumisato Y; Suzuki Y; Masaki T; Mori T; Sugiyama M; Fusco A; Atomi Y
J Gastroenterol; 2003; 38(12):1144-9. PubMed ID: 14714251
[TBL] [Abstract][Full Text] [Related]
7. Expression of Ep-CAM in normal, regenerating, metaplastic, and neoplastic liver.
de Boer CJ; van Krieken JH; Janssen-van Rhijn CM; Litvinov SV
J Pathol; 1999 Jun; 188(2):201-6. PubMed ID: 10398165
[TBL] [Abstract][Full Text] [Related]
8. Comparative immunohistochemical expression of p63 in human cholangiocarcinoma and hepatocellular carcinoma.
Ramalho FS; Ramalho LN; Della Porta L; Zucoloto S
J Gastroenterol Hepatol; 2006 Aug; 21(8):1276-80. PubMed ID: 16872309
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Glut-1 expression in cholangiocarcinoma, benign biliary lesions and hepatocellular carcinoma.
Zimmerman RL; Fogt F; Burke M; Murakata LA
Oncol Rep; 2002; 9(4):689-92. PubMed ID: 12066193
[TBL] [Abstract][Full Text] [Related]
10. Immunostaining for polycomb group protein EZH2 and senescent marker p16INK4a may be useful to differentiate cholangiolocellular carcinoma from ductular reaction and bile duct adenoma.
Sasaki M; Matsubara T; Kakuda Y; Sato Y; Nakanuma Y
Am J Surg Pathol; 2014 Mar; 38(3):364-9. PubMed ID: 24487593
[TBL] [Abstract][Full Text] [Related]
11. The utility of keratin 903 as a new prognostic marker in mass-forming-type intrahepatic cholangiocarcinoma.
Aishima S; Asayama Y; Taguchi K; Sugimachi K; Shirabe K; Shimada M; Sugimachi K; Tsuneyoshi M
Mod Pathol; 2002 Nov; 15(11):1181-90. PubMed ID: 12429797
[TBL] [Abstract][Full Text] [Related]
12. Hepatocarcinoma-intestine-pancreas/pancreatic associated protein (HIP/PAP) is expressed and secreted by proliferating ductules as well as by hepatocarcinoma and cholangiocarcinoma cells.
Christa L; Simon MT; Brezault-Bonnet C; Bonte E; Carnot F; Zylberberg H; Franco D; Capron F; Roskams T; Bréchot C
Am J Pathol; 1999 Nov; 155(5):1525-33. PubMed ID: 10550309
[TBL] [Abstract][Full Text] [Related]
13. Cellular and stromal characteristics in the scirrhous hepatocellular carcinoma: comparison with hepatocellular carcinomas and intrahepatic cholangiocarcinomas.
Okamura N; Yoshida M; Shibuya A; Sugiura H; Okayasu I; Ohbu M
Pathol Int; 2005 Nov; 55(11):724-31. PubMed ID: 16271085
[TBL] [Abstract][Full Text] [Related]
14. Pathology of combined hepatocellular-cholangiocarcinoma.
Yeh MM
J Gastroenterol Hepatol; 2010 Sep; 25(9):1485-92. PubMed ID: 20796144
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis.
Terada T; Nakanuma Y; Sirica AE
Hum Pathol; 1998 Feb; 29(2):175-80. PubMed ID: 9490278
[TBL] [Abstract][Full Text] [Related]
16. Mixed hepatocellular-cholangiocarcinoma may derive from "hepatogones".
Hunt JP; Varnholt H
Hepatobiliary Pancreat Dis Int; 2008 Feb; 7(1):105; author reply 105-6. PubMed ID: 18234649
[No Abstract] [Full Text] [Related]
17. Expression of apoptosis, proliferating cell nuclear antigen, and apoptosis-related antigens (bcl-2, c-myc, Fas, Lewis(y) and p53) in human cholangiocarcinomas and hepatocellular carcinomas.
Terada T; Nakanuma Y
Pathol Int; 1996 Oct; 46(10):764-70. PubMed ID: 8916146
[TBL] [Abstract][Full Text] [Related]
18. Cholangiocarcinomas arising in cirrhosis and combined hepatocellular-cholangiocellular carcinomas share apomucin profiles.
Sasaki M; Nakanuma Y; Ho SB; Kim YS
Am J Clin Pathol; 1998 Mar; 109(3):302-8. PubMed ID: 9495202
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic utility of GLUT1 in the differential diagnosis of liver carcinomas.
Roh MS; Jeong JS; Kim YH; Kim MC; Hong SH
Hepatogastroenterology; 2004; 51(59):1315-8. PubMed ID: 15362741
[TBL] [Abstract][Full Text] [Related]
20. Differential diagnosis of malignant epithelial tumours in the liver: an immunohistochemical study on liver biopsy material.
Al-Muhannadi N; Ansari N; Brahmi U; Satir AA
Ann Hepatol; 2011; 10(4):508-15. PubMed ID: 21911893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
